Contrast media-induced nephropathy: Clinical burden and current attempts for prevention;Kontrast madde nefropatisi: Klinik önemi ve önlenmesine yönelik güncel yaklaşimlar

Anadolu Kardiyoloji Dergisi

Volumn 5, Issue 2, 2005, Pages 124-129

  Habeb, Muhammed ^a   Aǧaç, Mustafa Tarik ^a   Aliyev, Farid ^a   Pehlivanoǧlu, Seçkin ^a   Öngen, Zeki ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Contrast media induced nephropathy; Prevention; Risk stratification

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; NONIONIC CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; AGE; ARTICLE; CARDIOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEHYDRATION; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; HYDRATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KIDNEY DISEASE; MORBIDITY; MORTALITY; PHYSICAL CHEMISTRY; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CONTRAST MEDIA; HUMANS; KIDNEY FAILURE, ACUTE; RISK ASSESSMENT;

EID: 20844441636     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Aspellin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high risk patients undergoing angiography. (NEFRIC study). N Eng J Med 2003; 348: 491-9.
2. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-aquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243-8.
3. Pflueger A, Larson TS, Nath KA, et al. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 2000; 75: 1275-83.
4. Gross P, Bussemaker E. Endotelin: what role in acute contrast nephropathy? Nephrol Dial Transplant 1996; 11: 1716-8.
5. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990; 258: F115-20.
6. Yoshioka T, Fago A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41: 1008-15.
7. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47: 254-61.
8. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320: 149-53.
9. Lepor NE. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and n-acetylcysteine. Rev in Cardiovasc Med 2003; 4: 15-20.
10. Cronin RE. Renal failure following radiologic procedures. Am J Med 1989;64:342-56
11. Porter GA. Contrast-associated nephropathy. Am J Cardiol 1989; 64: 22E-6E.
12. Porter GA. Expiremental contrast-associated nephropathy and its clinical implications. Am J Cardiol 1990; 66: 18F-22F.
13. Lisstro F, Falsini G, Bolognese L, et al. The clinical burden of contrast media-induced nephropathy: Ital Heart J 2003; 4: 668-76.
14. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patient with renal disease. Am J Med 1989; 86: 649-52.
15. Altmann DB, Zwas D, Spatz A. Use of contrast volume to estimate creatinine clearance ratio to predict renal failure after angiography. J Interven Cardiol 1997; 10: 113-9.
16. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64.
17. Mehran R, Aymong E, Dangas G et al. A risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol 2003;41 (Supplement A): 37A.
18. Toprak Ö, Cirit M, Bayata S, ve ark. Koroner anjiyografi yapilan hastalarda islem öncesi sol ventrikül ejeksiyon fraksiyonu ile kontrast madde nefropatisi arsinda ilşki varmi dir? T Klin Tip Bil Derg 2003; 23: 104-7.
19. Baim DS, Grossman W. Grosman's cardiac catheterization, angiography, and intervention. 6th ed. Philadelphia: Lippincot, Williams&Wilkins; 2000.
20. Barret BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-8.
21. Davidson CJ, Laskey WK, Hermiller JB et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000; 101: 2172-7.
22. Sutton AG, Ashton VJ, Campbell PG, et al. A randomized prospective trial of ioxaglate (Hexabrix) 320 and iodixanol (Visipaque) 320 in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2002; 57: 346-52.
23. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of in patient vs out patient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998; 114: 1570-4.
24. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast-media associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patient undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-36.
25. Brick R, Krzossok S, Markowetz F et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 589-603.
26. Briguori C, Colombo A, Violante A, et al. High versus low dose acetylcysteine to prevent contrast agent associated with nephrotoxicity. J Am Coll Cardiol 2003;41 (Supplement A): 39A (Abstract).
27. Baker CS, Wragg E, Kumar S, et al. A Rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003: 41; 2114-8.
28. Hunter Dw, Chamsuddin A, Bjarnason H, et al. Preventing contrast-induced nephropathy with fenoldopam. Tech Vasc Interv Radiol 2001; 4: 53-6.
29. Chamsuddin AA, Kowalik KJ, Bjarnason H, et al. Using a dopamine type 1A receptor agonist in high-risk patient to ameliorate contrast-associated nephropathy. Am J Roengenol 2002; 179: 591-6.
30. Madyoon H, Croushore L, Weaver D, et al. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients . Catheter Cardiovas Interv 2001; 53: 341-5.
31. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-91.
32. Huber W, Ilgman K, Page M, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insuficiency: controlled, randomized, double-blinded study. Radiology 2002; 223: 772-9.
33. Marenzi G, Marana I, Lauri G et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Eng J Med 2003; 349: 1333-40.
34. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413-5.
35. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Eng J Med 1994; 331: 1416-20.
36. Wang YXJ, Jia YF, Chen KM, et al. Radiographic contrast media induced nephropathy: experimental observations and protective effect of calcium channel blokers. Br J Radiol 2001; 74: 1103-8.
37. Safian RD, Freed M. The Manual of Interventional Cardiology. 3rd. ed. Royal Oak, MI: Physicians Press; 2001.
38. Mc Cullough PA, Walyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75.